Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Apisarnthanarax, Smith; Alauddin, Mian M.; Mourtada, Firas; Ariga, Hiroyoshi; Raju, Uma; Mawlawi, Osama; Han, Dongmei; Bornmann, William G.; Ajani, Jaffer A.; Milas, Luka; Gelovani, Juri G.; Chao, K.S. Clifford

doi:10.1158/1078-0432.ccr-05-2720

Cited by 71 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on its TK1-related signal, [ 18 F]FLT PET has been proposed as a biomarker for predicting (early) response to systemic or locoregional treatment [12][13][14]. Recent studies have shown that [ 18 F]FLT PET can predict response to therapy as early as 1 week after treatment [15], and a decrease in [ 18 F]FLT uptake seems to be correlated with prolonged overall survival [16,17].…”

mentioning

confidence: 99%

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Langen

Klabbers

Lubberink

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Positron emission tomography (PET) using 18 F-3′-deoxy-3′-fluorothymidine ([ 18 F]FLT) allows noninvasive monitoring of tumour proliferation. For serial imaging in individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative [ 18 F]FLT measurements. Methods Nine patients with non-small-cell lung cancer (NSCLC) and six with head-and-neck cancer (HNC) underwent [ 18 F]FLT PET twice within 7 days prior to therapy. The maximum pixel value (SUV max ) and a threshold defined volume (SUV 41% ) were defined for all delineated lesions. The plasma to tumour transfer constant (K i ) was estimated using both Patlak graphical analysis and nonlinear regression (NLR). NLR was also used to estimate k 3 , which, at least in theory, selectively reflects thymidine kinase 1 activity. The level of agreement between test and retest values was assessed using the intraclass correlation coefficient (ICC) and Bland-Altman analysis. Results All primary tumours and >90% of clinically suspected locoregional metastases could be delineated. In total, 24 lesions were defined. NLR-derived K i , Patlakderived K i , SUV 41% and SUV max showed excellent reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and SDs of 16%, 12%, 7% and 11%, respectively. Reproducibility was poor for k 3 with an ICC of 0.43 and SD of 38%. Conclusion Quantitative [ 18 F]FLT measurements are reproducible in both NSCLC and HNC patients. When monitoring response in individual patients, changes of more than 15% in SUV 41% , 20-25% in SUV max and Patlak-derived K i , and 32% in NLR3k-derived K i are likely to represent treatment effects.

show abstract

mentioning

confidence: 99%

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Langen

Klabbers

Lubberink

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…PET imaging uses radiopharmaceuticals labeled with positron emitting radioisotopes such as 11 C, 13 N, 15 O, and 18 F, which are produced in a cyclotron, and 68 Ga and 82 Rb, which are produced in a radioisotope generator. After a positron is emitted, it annihilates with a nearby electron and generates 2 annihilation photons (each with an energy of 511 keV), which travel in opposite directions.…”

Section: Principles Of Pet Imagingmentioning

confidence: 99%

“…9 Thus, although SUVs do not provide an accurate absolute measure of tumor glucose use, they are useful for assessing interval change in metabolism, because many of the confounding issues with SUVs are negated by measuring relative change. With properly calibrated imaging devices and adherence to standard patient preparation and imaging protocols, the test-retest F-ISO-1, N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18 Ffluoroethoxy)-5-methylbenzamide; 18 F-ML-10, 18 F-radiolabeled derivative of malonic acid; 68 Ga-DOTA-TOC, 68 Ga-DOTA-Tyr 3 -octreotide; 68 Ga-PSMA, 68 Ga-radiolabeled prostate-specific membrane antigen ligand; FDA, US Food and Drug Administration; PSMA, prostate-specific membrane antigen.…”

Section: Fdg-pet Backgroundmentioning

confidence: 99%

“…Recently, both 18 68 Ga-PSMA have been studied in humans, and both reportedly were capable of detecting sites of metastatic prostate cancer. 125,126 In a subsequent, small clinical trial, 68 Ga-PSMA detected more lesions than 18 F-choline. 127 Somatostatin receptors are overexpressed on neuroendocrine tumor cells.…”

Section: Imaging Protein and Cell Membrane Metabolismmentioning

confidence: 99%

“…Imaging of this biomarker is currently accomplished using SPECT with 111 Indiethylenetriaminepentaacetic acid (DTPA)-octreotide; however, several new radiotracers have been developed that can be imaged using PET. Examples include 68 Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Tyr 3 -octreotide ( 68 Ga-DOTA-TOC), 68 Ga-DOTA-1-Nal 3 -octreotide ( 68 Ga-DOTA-NOC), and 68 Ga-DOTA-Tyr 3 -octreotate (DOTA-TATE), all of which demonstrate better sensitivity than 111 In-DTPA-octreotide for neuroendocrine tumors, and all have the additional benefit of better resolution because they are imaged using PET. 128 Although all 3 radiotracers demonstrate variable affinity to somatostatin receptor subtypes, there is currently no evidence of a clinical impact from these differences; thus, there is no indication suggesting the preferential use of one compound over the others.…”

Section: Imaging Protein and Cell Membrane Metabolismmentioning

confidence: 99%

See 2 more Smart Citations

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

191

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

DW‐MRI and ¹⁸F‐FLT PET for early assessment of response to radiation therapy associated with hypoxia‐driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation

Tran

Bol

Labar

et al. 2015

Contrast Media & Molecular

View full text Add to dashboard Cite

Early markers of treatment response may help in the management of patients by predicting the outcome of a specific therapeutic intervention. Here, we studied the potential value of diffusion-weighted MRI (DW-MRI) and (18)F-fluorothymidine ((18)F-FLT), markers of cell death and cell proliferation respectively, to predict the response to irradiation. In addition, dose escalation and/or carbogen breathing were used to modulate the response to irradiation. The studies were performed on two hypoxic rat tumor models: rhabdomyosarcoma and 9L-glioma. The rats were imaged using MRI and PET before and two days after the treatment. In both tumor models, changes in ADC (apparent diffusion coefficient) and (18)F-FLT SUV (standardized uptake value) were significantly correlated with the tumor growth delay. For both tumor models, the ADC values increased in all irradiated groups two days after the treatment while they decreased in the untreated groups. At the same time, the uptake of (18)F-FLT increased in the untreated groups and decreased in all treated groups. Yet, ADC values were not sensitive enough to predict the added value of dose escalation or carbogen breathing in either model. Change in (18)F-FLT uptake was able to predict the higher tumor response when using increased dose of irradiation, but not when using a carbogen breathing challenge. Our results also emphasize that the magnitude of change in (18)F-FLT uptake was strongly dependent on the tumor model.

show abstract

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Cited by 71 publications

References 30 publications

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

PET/CT imaging in cancer: Current applications and future directions

DW‐MRI and ¹⁸F‐FLT PET for early assessment of response to radiation therapy associated with hypoxia‐driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation

Contact Info

Product

Resources

About

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Cited by 71 publications

References 30 publications

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

PET/CT imaging in cancer: Current applications and future directions

DW‐MRI and 18F‐FLT PET for early assessment of response to radiation therapy associated with hypoxia‐driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation

Contact Info

Product

Resources

About

DW‐MRI and ¹⁸F‐FLT PET for early assessment of response to radiation therapy associated with hypoxia‐driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation